Docality.com Logo
 
Dr. Clifford  Wong  Md image

Dr. Clifford Wong Md

1999 Mowry Ave Suite R
Fremont CA 94538
510 458-8186
Medical School: University Of California, San Diego School Of Medicine - 1997
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: Yes
License #: A68265
NPI: 1780621706
Taxonomy Codes:
174400000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Clifford Wong is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:90960 Description:Esrd srv 4 visits p mo 20+ Average Price:$684.00 Average Price Allowed
By Medicare:
$311.50
HCPCS Code:99291 Description:Critical care first hour Average Price:$571.00 Average Price Allowed
By Medicare:
$233.76
HCPCS Code:90961 Description:Esrd srv 2-3 vsts p mo 20+ Average Price:$569.00 Average Price Allowed
By Medicare:
$259.56
HCPCS Code:99223 Description:Initial hospital care Average Price:$341.00 Average Price Allowed
By Medicare:
$211.97
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$307.00 Average Price Allowed
By Medicare:
$179.48
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$268.00 Average Price Allowed
By Medicare:
$157.83
HCPCS Code:90935 Description:Hemodialysis one evaluation Average Price:$164.00 Average Price Allowed
By Medicare:
$79.46
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$189.00 Average Price Allowed
By Medicare:
$118.09
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$171.00 Average Price Allowed
By Medicare:
$109.13
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$119.00 Average Price Allowed
By Medicare:
$76.22

HCPCS Code Definitions

99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
90935
Hemodialysis procedure with single evaluation by a physician or other qualified health care professional
90960
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
90961
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1255478772
Internal Medicine
4,893
1881642155
Internal Medicine
4,077
1316958143
Internal Medicine
2,553
1528056389
Hematology/Oncology
2,246
1508849860
Cardiovascular Disease (Cardiology)
2,228
1689621765
Nephrology
1,819
1831203652
Internal Medicine
1,818
1417974460
Vascular Surgery
1,778
1417068511
Gastroenterology
1,758
1144337866
General Surgery
1,712
*These referrals represent the top 10 that Dr. Wong has made to other doctors

Publications

ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution. - Protein engineering, design & selection : PEDS
The CTLA4-Ig therapeutics abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) co-stimulatory ligands. Both compounds preferentially bind CD80, yet CD86 has been implicated as the dominant co-stimulatory ligand. Using directed evolution methods, novel CTLA4-Ig variants were created with selective CD86 binding affinity, a property that confers increased immunosuppressive potency and potentially improved efficacy and safety profiles. Relative to abatacept (wild-type CTLA4-Ig), ASP2408 and ASP2409 have 83-fold and 220-fold enhanced binding affinity to CD86 while retaining 1.5-fold and 5.6-fold enhanced binding affinity to CD80, respectively. Improvements in CD86 binding affinity correlates with increased immunosuppressive potencyin vitroandin vivo Our results highlight the power of directed evolution methods to obtain non-intuitive protein engineering solutions and represent the first examples of CD86-selective CTLA4-Ig compounds that have entered clinical trials.© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. - Digestive diseases and sciences
Chronic hepatitis B (CHB) is a major cause of cirrhosis and end-stage liver disease. Not all patients with CHB require antiviral treatment but long-term monitoring is critical to identify patients who would benefit from antiviral therapy. CHB patients followed in various clinical settings may differ in disease characteristics and rates of treatment eligibility in long-term follow-up.We conducted a retrospective cohort study of 359 consecutive treatment-naive, treatment-ineligible CHB patients (228 from community GI clinics; 73 from university hepatology clinic; 58 from primary care clinic). Primary end points were the proportion of patients meeting eligibility criteria in follow-up, and the eligibility comparison among patients in various clinical settings. Univariate and multivariate Cox's proportional hazard models were used to calculate hazard ratios to identify predictors of treatment eligibility in follow-up.While the majority of patients remained treatment ineligible by guideline recommendations, a sizeable proportion (23 %, 95 % CI 18-27 %) of patients subsequently met treatment eligibility in study follow-up. Reasons for meeting US Panel treatment eligibility on multivariate analysis included baseline ALT ≥ ULN (HR 1.91, p = 0.03) and baseline HBV DNA ≥ 2000 IU/mL (HR 2.6, p = 0.001). Practice setting was not a predictor.A significant number of patients with CHB (23 %) who were not initially treatment eligible later met treatment criteria in longer-term follow-up. Significant independent predictors of treatment eligibility included a baseline ALT ≥ ULN and elevated HBV DNA (≥2000 IU/mL for US Panel eligibility and ≥20,000 IU/mL for AASLD eligibility). This study underscores the importance of long-term follow-up for patients with CHB.
Entire-volume serial histological examination for detection of micrometastases in lymph nodes of colorectal cancers. - Pathology oncology research : POR
The purpose of this study was to accurately detect lymph-node micrometastases, i.e., metastatic cancer foci that have a size between 2.0 and 0.2 mm, in nodes excised from colorectal cancer (CRC) patients, and to determine how frequently micrometastases might be missed when standard histological examination procedures are used. A total of 311 lymph nodes were removed and examined from 90 patients with Stage I to IV CRC. The number of slices of histology sections ranged from 6 to 75 per node (average = 25.5; SD = 11.1), which provided a total of 7,943 slices. Lymph nodes were examined in their entire volume at every 50-μm and 100-μm intervals for nodes smaller and larger than 5 mm respectively. The total number of thin sections examined in each node and the number of thin sections where metastatic foci were present were counted. The number of thin sections with metastatic foci and the total number of slices was determined for each node. In addition, the presence or absence of metastatic foci in the "central" slice was determined. Micrometastases were found in 12/311 (3.9%) of all lymph nodes. In the 12 lymph nodes with micrometastases, the rate of metastatic slices over all slices was 39.4% (range = 6.3 to 81.3%; SD = 25.8%) In the central slice of each node, micrometastases were present only in 6 of 12 lymph nodes (50%); accordingly, they were not present in the central slice for half the micrometastatic nodes. These 6 nodes represented 1.9% of the 311 nodes and 11.1% of the 54 metastatic nodes. This study suggests that a significant fraction of micrometastases can be missed by traditional singleslice sectioning; half of the micrometastases would have been overlooked in our data set of 311 nodes.
The angiotensin II receptor (Agtr1a): functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. - Physiological genomics
Hypertension is a complex trait with multiple genetic determinants. A previous genome-wide linkage study of systolic blood pressure in a mouse genetic backcross implicated a region of chromosome 13 (LOD = 3.3 at 16.0 cM) as a determinant of blood pressure differences between a hereditary low blood pressure strain of Mus musculus (BPL/1) and Mus spretus (SPRET); at this locus, the unexpected effect of the BPL/1 allele was to increase blood pressure. A plausible candidate locus encoding angiotensin II receptor isoform 1a (Agtr1a) is also located at 16.0 cM on chromosome 13. We therefore investigated structural and functional differences at Agtr1a between BPL/1 and SPRET, as well as the BPH/2 strain. Resequencing Agtr1a in the three strains established the exon/intron and proximal promoter structure of the mouse gene. Coding exon 3 spanned 1,960 bp (with 26 SNPs), including the 1,077-bp/359-amino acid ORF (with 5 cSNPs, all of which were synonymous). Promoter sequences revealed a consensus TATA box, conserved G/C-rich regions, and a striking, lengthy simple sequence repeat region, composed of di-, tri-, tetra-, and penta-nucleotide repeats, whose overall length varied markedly among the strains. Twenty-five other SNPs and three single nucleotide deletions differentiated the strains' promoters, six of which were in likely functional promoter motifs. Agtr1a mRNA abundance in the adrenal gland in vivo was greater (P < 0.05) in BPL/1 than SPRET, consistent with the predicted effect of the BPL/1 allele to confer higher blood pressure. When Agtr1a promoters were subcloned into luciferase reporter plasmids and transfected into PC12 chromaffin cells, basal promoter expression was higher (P < 0.001) in BPL/1 than in SPRET, consistent with the endogenous mRNA results. In summary, Agtr1a on chromosome 13 is highly polymorphic between mouse strains, although the amino acid sequence specified by the ORF is invariant, even across mouse species. We conclude that polymorphisms in the Agtr1a promoter account for differences in gene expression in vivo between BPL/1 and SPRET, in a way consistent with the effects of alleles at this locus on chromosome 13 to affect blood pressure in the mouse genome-wide linkage study.

Map & Directions

1999 Mowry Ave Suite R Fremont, CA 94538
View Directions In Google Maps

Nearby Doctors

3200 Kearney St
Fremont, CA 94538
510 901-1222
39200 Liberty St Suite D
Fremont, CA 94538
510 979-9711
40000 Fremont Blvd Ste A
Fremont, CA 94538
650 781-1387
2299 Mowry Ave
Fremont, CA 94538
510 915-5374
3200 Kearney St
Fremont, CA 94538
510 901-1222
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 953-3000
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 953-3000
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 483-3000
2287 Mowry Ave Suite C
Fremont, CA 94538
510 932-2645
2243 Mowry Ave Ste A
Fremont, CA 94538
510 929-9777